We are live on ! Find out more
JSPR icon

Jasper Therapeutics

85 hedge funds and large institutions have $335M invested in Jasper Therapeutics in 2024 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 30 increasing their positions, 15 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

147% more call options, than puts

Call options by funds: $6.82M | Put options by funds: $2.76M

100% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 15

82% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 11

66% more capital inflows, than outflows

Capital inflows: $55.8M | Capital outflows: $33.6M

12% more funds holding

Funds holding: 76 → 85 (+9)

7.18% more ownership

Funds ownership: 97.19% → 104.36% (+7.2%)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
85
Holders Change
+9
Holders Change %
+11.84%
% of All Funds
1.11%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
20
Increased
30
Reduced
15
Closed
11
Calls
$6.82​M
Puts
$2.76​M
Net Calls
+$4.06​M
Net Calls Change
+$2.07​M

JSPR Hedge Fund Activity: Q4 2024 in Review

85 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q4 2024, worth a combined $335M — up 22% from $275M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new JSPR positions and 11 closed out — a net gain of 9 holders — while 30 added to existing stakes and 15 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $7.29M. The largest seller was Polar Capital Holdings, exiting entirely with an estimated $10.9M sold.

  • 85 institutional investors held Jasper Therapeutics (JSPR) as of Q4 2024, up from 76 in Q3 2024.
  • Funds reported $335M of Jasper Therapeutics stock for Q4 2024, up 22% quarter-over-quarter.
  • 20 funds opened new Jasper Therapeutics positions in Q4 2024 and 11 closed out, a net change of +9 holders.
  • The largest Jasper Therapeutics buyer in Q4 2024 was Fidelity Investments, an estimated $7.29M added.
  • The largest Jasper Therapeutics seller in Q4 2024 was Polar Capital Holdings, an estimated $10.9M sold.

Based on aggregated 13F filings for Q4 2024.